Yan Rolland

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Étienne Garin, Lambros Tselikas, Boris Guiu et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 604 citations

Medicine, Oncology, Radiation Oncology +17

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma

Julien Edeline, Yann Touchefeu, Boris Guiu et al. · JAMA Oncology · 2019 · 293 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Dosimetry Based on ^99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with ⁹⁰Y-Loaded Glass Microspheres: Preliminary Results

Étienne Garin, Laurence Lenoir, Yan Rolland et al. · Journal of Nuclear Medicine · 2012 · 276 citations · Full text

Medicine, Nuclear Medicine, Oncology +13

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Julien Edeline, Éveline Boucher, Yan Rolland et al. · Cancer · 2011 · 274 citations · Full text

Medicine, Oncology, Radiology +17